How Research is Turning the Tide on Triple-Negative Breast Cancer

| October 28, 2026
Scientifically reviewed by Priya Malhotra, PhD

From PARP inhibitors to antibody-drug conjugates, research is steadily expanding treatment options for triple-negative breast cancer.

Why triple-negative breast cancer therapy is an uphill battle

Most therapeutic success stories in breast cancer are because of the rational design of therapies. Researchers were able to uncover the right therapeutic target in estrogen receptor (ER)–positive tumors, which largely depend on estrogen, and HER2-positive tumors, which depend on HER2 signaling. By blocking certain pathways and the cancers’ growth, these drugs ultimately proved effective for most breast cancer cells. But for triple-negative breast cancer (TNBC), therapeutic targets—molecular processes that cancer cells need to survive—have been much more difficult to find.

Researchers fully understand the urgency of this disease, which has historically been without viable targeted therapies because it’s defined by the fact that it lacks three major factors used to classify and more effectively treat breast cancer: ER, PR (progesterone receptor), and HER2. Inherently, TNBC is more aggressive, tends to be diagnosed at an earlier age than other breast cancers, and is overrepresented among Black patients and BRCA mutation carriers. But if we take a step back to look at progress in the field over the years, there are new reasons to feel hopeful.

Until recently, the 10 to 15% of breast cancer patients diagnosed with TNBC were restricted to less-targeted therapeutic mainstays: chemotherapy and radiation. While these therapies are highly effective at killing tumor cells and have saved millions of lives, they may also have toxic side effects as they can affect some healthy cells in the body.

Over the years, as molecular sequencing and analysis technologies advanced, scientists doggedly probed TNBC for new therapeutic targets. This catchall subtype of breast cancer can differ widely from patient to patient and can adapt to resist therapies, making targets even harder to pin down, and a few trials assessing targeted therapies failed in the 2010s. But all the while, researchers continued studying TNBC, identifying and defining drivers of the disease, and refining existing therapies—testing different types of chemo drugs, trying new combinations, treating early-stage patients before surgery. Because of that work, response rates did improve.

New treatments for triple-negative breast cancer

As more sophisticated analytical technologies, exciting discoveries in the broader cancer field, identification of targets for specific TNBC subsets, and new drugs emerged, the limited toolbox of options for treating TNBC has expanded to a small but growing arsenal of options. Among them:

PARP Inhibitors

People with TNBC who have inherited mutations in a BRCA gene (approximately 15% of patients) may be treated with PARP inhibitors. These drugs inflict catastrophic DNA damage on cancer cells that lack functional BRCA1 or BRCA2 DNA repair genes. Two therapies, talazoparib (Talzenna®) and olaparib (Lynparza®), were approved for metastatic, HER2-negative breast cancer in 2018. Olaparib is also approved for people with high-risk, early-stage HER2-negative breast cancer after surgery and chemotherapy, where it lowers the risk of the cancer coming back.

Immunotherapy

Over the last decade, many researchers shifted their focus from targeting cancer cells to activating the immune system to eradicate tumors. The combination of pembrolizumab (Keytruda®)—a type of immunotherapy called a checkpoint inhibitor—with chemotherapy was practice-changing for patients with TNBC tumors that express PD-L1, an important immune marker. First approved for metastatic TNBC, Keytruda is now being used in high-risk early-stage TNBC as well. Immunotherapy holds incredible promise and there is still much more to learn.

Antibody-drug conjugates

A major challenge in cancer therapy is the fact that lifesaving drugs can impact healthy cells. Game-changing antibody-drug conjugates (ADCs) aim to address this by delivering drugs directly to tumors through cancer-cell specific antibodies. ADCs are engineered to contain a target-specific antibody linked to a toxic drug payload. Once the antibody recognizes and binds to its target, the payload is released. This technology was used to create an ADC called sacituzumab govitecan (Trodelvy®) that was approved for metastatic TNBC in 2020. This ADC contains an antibody that attaches to Trop2, a protein present on many breast cancer cells, including TNBC cells. More recently, the FDA expanded approval of another ADC called trastuzumab durextecan (Enhertu®) to include patients with low and ultralow levels of HER2. Some patients whose tumors are classified as TNBC may actually have low levels of HER2 and could benefit from this treatment. 

The latest triple-negative breast cancer breakthroughs

The past two years have brought some of the biggest changes yet in how TNBC is treated. Antibody-drug conjugates have moved earlier in treatment, and researchers are finding new ways to make immunotherapy work for more patients.

Antibody-drug conjugates move into first-line treatment

Antibody-drug conjugates like sacituzumab govitecan (Trodelvy®) have emerged as effective treatments for TNBC. Researchers continue to leverage this technology to develop more ADCs. In fact, another Trop2-directed ADC called datopotamab deruxtecan (Datroway®) was FDA approved in 2025 for HR-positive/HER2-negative breast cancer. In May 2026, the FDA approved Datroway for people with metastatic TNBC who are not candidates for immunotherapy, based on the phase 3 TROPION-Breast02 trial. That trial demonstrated that Datroway had statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy. Median overall survival was 23.7 months with Datroway, compared with 18.7 months with chemotherapy.

In June 2026, the FDA also approved Trodelvy as a first-line treatment for metastatic TNBC, both on its own for people who are not candidates for immunotherapy and together with pembrolizumab (Keytruda®) for people whose tumors express PD-L1. Together, these approvals make antibody-drug conjugates a first-line option for metastatic TNBC for the first time.

This is hopeful news for patients with TNBC, particularly those for whom immunotherapy is not an option. Researchers are also testing novel treatment combinations and optimizing drug therapies with regards to timing and sequencing, including with different ADCs. 

Expanding the reach of immunotherapy

The immunotherapy drug pembrolizumab (Keytruda®) combined with chemotherapy is now a standard treatment for high-risk early-stage TNBC in the neoadjuvant and adjuvant setting. And pembrolizumab with chemotherapy is also approved for PD-L1 positive metastatic TNBC as a first-line option. But researchers are steadily working to optimize immunotherapy effectiveness and expand its use, including:  

  • Seeking new immune checkpoint targets and combinations, such as combining checkpoint inhibitors with chemotherapy or radiation
  • Exploring novel immunotherapy approaches like vaccines, adoptive T-cell therapies, and immune-modulating nanotechnologies
  • Identifying biomarkers to predict which patients will benefit most from immunotherapy

Continuing progress against triple-negative breast cancer

BCRF investigators have been integral to many of these advancements and their engagement in clinical trials now—and, no doubt, in the future—will keep propelling TNBC research forward. About 25% of BCRF-funded projects touch on TNBC, and BCRF is supporting studies exploring immunology, metastasis, new drug combinations, and other pressing challenges. Researchers will keep working to unpack this complex disease.

There is still so much more to learn, but as BCRF investigator Dr. Lisa Carey has said: “I think we’ve turned the corner, and that’s why I have some excitement about where things are going.”

In just over a decade, people with TNBC have more options: PARP inhibitors, immunotherapy, and a growing set of antibody-drug conjugates. Each of these came from years of foundational research, and the next generation of treatments is already being tested.

Support the research driving these discoveries. Donate, start a fundraiser, or explore other ways to give and help fund the science that’s bringing new treatments to people with triple-negative breast cancer.

Frequently asked questions

What is the survival rate for triple-negative breast cancer?

According to the American Cancer Society, the 5-year relative survival rate for women diagnosed with TNBC between 2015 and 2021 was 92% when the cancer was found only in the breast, 67% when it had spread to nearby lymph nodes, and 15% when it had spread to distant parts of the body. These survival rates reflect treatments available years ago, so people diagnosed today may have a better outlook.

Can triple-negative breast cancer come back after treatment?

Yes. TNBC is more likely than other types of breast cancer to come back in the first few years after diagnosis, with the risk peaking at around three years. After five years, the risk drops sharply and is no longer higher than for other breast cancers.

How can I find a clinical trial for triple-negative breast cancer?

Start by asking your oncologist which trials might fit your diagnosis. You can also search ClinicalTrials.gov or call the National Cancer Institute’s Cancer Information Service at 1-800-4-CANCER for help finding a trial. Many of the newest TNBC treatments first became available to patients through clinical trials.

legacy-Society

Support research with a legacy gift. Sample, non-binding bequest language:

I give to the Breast Cancer Research Foundation, located in New York, NY, federal tax identification number 13-3727250, ________% of my total estate (or $_____).

Learn More